Tag Archives: Andrew Dillon

Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines

Posted on July 19, 2011 by Barbara Arzymanow

The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading →

Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research | Tagged 2020health, Alzheimer's Disease, Andrew Dillon, Andrew lansley, Department of Health, Drugs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, patient access, Patients, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing | Leave a comment

	Lali Sekhon, MD on Tackling obesity – What the UK…
	Author Ingrid Hall on Ovarian Cancer – Make wo…
	David Bradley on 2020health comments on GMC rep…
	20 things to make yo… on Equal treatment for Depression…
	David Bradley on Guest Blogspot: Misleading, Bi…

Tag Archives: Andrew Dillon

Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines

TwentyTwentyTweets

Email Subscription

Recent Posts

Pages

Opinions

Categories